| Name | Title | Contact Details |
|---|
Octave is developing a comprehensive, first-in-class Care Management Platform.
Novartis Consumer Health Inc is a Big Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kiadis Pharma is a clinical stage biopharmaceutical company focused on developing innovative and potentially life-saving therapies for blood cancer patients where pharmacological standard of care is no longer an alternative. The Company`s main focus is on the development of a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients, thus making them safe and available as the last potentially life saving option. Stem cell transplantation is currently the only potentially curative treatment available for late stage blood cancer patients; however, a standard of care matching donor is only available for half of patients who are progressing with radiation therapy and chemotherapy.
Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience Inc. is developing a novel and proprietary class of product candidates that are designed to target the body`s nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics. NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS. To become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.
ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer`s disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer`s disease, but other Neurodegenerative Conditions such as Huntington`s disease, Parkinson`s disease and MS, and recover quality of life for those patients and their families.